


# Hope for Alzheimer's blood test

July 21 2022



Boxplots comparing plasma Aβ1-42/Aβ1-40 ratio, p-tau181, GFAP, and NfL between CU Aβ-, CU Aβ+, MCI Aβ-, MCI Aβ+, and AD Aβ+ groups at timepoint 1. Plasma measures were compared between groups using linear models with age, sex, APOE ε4 carrier status, PET tracer, and site as covariates. Data from 81 CU Aβ-, 39 CU Aβ+, 26 MCI Aβ-, 33 MCI Aβ+, and 46 AD Aβ+ participants were utilized for analyses. The line segments within each boxplot represent the median of the data. p-values were obtained from natural log-transformed plasma biomarker data to better approximate normality and variance homogeneity. *p* Alzheimer's & Dementia (2022). DOI: 10.1002/alz.12724

Researchers from Macquarie University's Centre for Ageing, Cognition and Wellbeing are one step closer to a blood test to diagnose Alzheimer's early in the disease's progression.

Professor Ralph Martins and colleague Dr. Pratishtha Chatterjee are lead authors on a paper in *Alzheimer's & Dementia* showing that several [blood biomarkers](#) reflect the core hallmarks of Alzheimer's disease, which is the most common form of dementia.

Professor Martins says current standard clinical testing only provides a possible or probable diagnosis of Alzheimer's.

"Cerebrospinal fluid samples and brain imaging that can confirm if someone has Alzheimer's, but these are invasive and expensive, so they are not commonly done," he says.

"Blood biomarkers would be cheap, easily accessible and have the ability to deliver high throughput testing."

"It's important to be able to confirm a diagnosis early on, as this will allow patients and their families to be better prepared for future challenges, provide opportunities for them to be involved in [clinical trials](#), and lower the cost of screening participants for these trials."

The study makes use of data from the Australian Imaging Biomarker and Lifestyle Study of Aging (AIBL).

Dr. Chatterjee says they found that a panel of blood-based biomarkers, including [amyloid beta](#) (A $\beta$ 42/40 ratio), phosphorylated-tau181 (p-tau181), and glial fibrillary acidic protein (GFAP), had high discriminative performance for Alzheimer's disease from preclinical to dementia stages with an accuracy of 85 to 95 percent.

"We also showed that low plasma A $\beta$  and high p-tau181, GFAP and neurofilament light chain (NFL) levels were associated with faster future cognitive decline, and low plasma A $\beta$  and high p-tau181 and GFAP were associated with faster future brain A $\beta$  accumulation," she says.

"Over 36 months, plasma A $\beta$  decreased, and p-tau181 and GFAP increased, at a faster rate in people with [mild cognitive impairment](#) when compared to healthy people, and GFAP and NFL increased at a faster rate in Alzheimer's disease when compared to healthy individuals."

Dr. Chatterjee says further investigation will now be required to validate the clinical cut-off points for implementation in [clinical settings](#), including looking at people from multiple ethnic backgrounds and those with comorbidities.

**More information:** Pratishtha Chatterjee et al, Plasma A $\beta$ 42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort, *Alzheimer's & Dementia* (2022). [DOI: 10.1002/alz.12724](https://doi.org/10.1002/alz.12724)

Provided by Macquarie University

Citation: Hope for Alzheimer's blood test (2022, July 21) retrieved 14 March 2023 from <https://medicalxpress.com/news/2022-07-alzheimer-blood.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.